Table 4.
Summary of adverse events in the intention-to-treat population
| Pyronaridine–artesunate (n = 101) | Artemether–lumefantrine (n = 96) | |
|---|---|---|
| Adverse event leading to discontinuation of study drug | ||
| Vomiting | 1 (0.99) | 1 (1.04) |
| Adverse event of any cause | ||
| Patients with at least 1 event | 42 (41.6) | 33 (34.4) |
| Headache | 10 (9.90) | 10 (10.4) |
| Vomiting | 10 (9.90) | 5 (5.21) |
| Cough | 18 (17.8) | 15 (15.6) |
| Abdominal pain | 3 (2.97) | 6 (6.25) |
| Anorexia | 4 (3.96) | 6 (6.25) |
| Diarrhoea | 2 (1.98) | 4 (4.17) |
| Chills | 2 (1.98) | 0 |
| Fatigue | 4 (3.96) | 1 (1.04) |
| Myalgia | 1 (0.99) | 1 (1.04) |
| Nasopharyngitis | 3 (2.97) | 4 (4.17) |
| Dizziness | 1 (0.99) | 0 |
| Skin rash | 2 (1.98) | 1 (1.04) |
| Dark urine | 1 (0.99) | 1 (1.04) |
| Ear pain | 0 | 1 (1.04) |
| Chest pain | 0 | 2 (2.08) |
| Throat pain | 1 (0.99) | 0 |
| Neck pain | 0 | 1 (1.04) |
Data are n (%)